PURPOSE: The use of basiliximab induction increased significantly in recent years based on its superior efficacy and excellent safety profile demonstrated in studies with cyclosporine-based immunosuppression. However, its clinical utility in patients receiving tacrolimus-based immunosuppressive regimens is still uncertain. METHODS: We retrospectively reviewed data of 366 low immunological risk recipients of deceased donor kidney transplants. Of them, 134 received basiliximab and tacrolimus (TAC-IL2-RA), 100 received basiliximab and delayed tacrolimus(dTAC-IL2-RA), and 132 patients received tacrolimus without basiliximab(TAC-No). The endpoints were the incidence of acute rejection, graft function, and patient and graft survivals at 1 year. RESULTS: The incidence of acute rejection was higher in dTAC-IL2-RA compared to TAC-IL-2RA and TAC-No Groups (33 vs.14.9 vs. 14.3 %, p < 0.001). Inferior creatinine clearance was observed in dTAC-IL2-RA Group compared to TAC-IL2-RA and TAC-No Groups at months 1 (41.6 vs. 49.9 vs. 44.8 mL/min, p = 0.004), 3 (49.8 vs. 57.2 vs. 53.5 mL/min, p = 0.017), and 6 (53.1 vs. 61.8 vs. 57.0 mL/min, p = 0.001). Patients who received basiliximab (TAC-IL2-RA and dTAC-IL2-RA Groups) had lower incidence of posttransplant diabetes (24 vs.18 vs. 39.3 %, p = 0.009). Patient and graft survivals were similar among the groups. CONCLUSIONS: In low immunological risk kidney transplant recipients receiving tacrolimus, the use of basiliximab induction was not associated with lower rejection rates and did not allow delayed tacrolimus introduction.
PURPOSE: The use of basiliximab induction increased significantly in recent years based on its superior efficacy and excellent safety profile demonstrated in studies with cyclosporine-based immunosuppression. However, its clinical utility in patients receiving tacrolimus-based immunosuppressive regimens is still uncertain. METHODS: We retrospectively reviewed data of 366 low immunological risk recipients of deceased donor kidney transplants. Of them, 134 received basiliximab and tacrolimus (TAC-IL2-RA), 100 received basiliximab and delayed tacrolimus(dTAC-IL2-RA), and 132 patients received tacrolimus without basiliximab(TAC-No). The endpoints were the incidence of acute rejection, graft function, and patient and graft survivals at 1 year. RESULTS: The incidence of acute rejection was higher in dTAC-IL2-RA compared to TAC-IL-2RA and TAC-No Groups (33 vs.14.9 vs. 14.3 %, p < 0.001). Inferior creatinine clearance was observed in dTAC-IL2-RA Group compared to TAC-IL2-RA and TAC-No Groups at months 1 (41.6 vs. 49.9 vs. 44.8 mL/min, p = 0.004), 3 (49.8 vs. 57.2 vs. 53.5 mL/min, p = 0.017), and 6 (53.1 vs. 61.8 vs. 57.0 mL/min, p = 0.001). Patients who received basiliximab (TAC-IL2-RA and dTAC-IL2-RA Groups) had lower incidence of posttransplant diabetes (24 vs.18 vs. 39.3 %, p = 0.009). Patient and graft survivals were similar among the groups. CONCLUSIONS: In low immunological risk kidney transplant recipients receiving tacrolimus, the use of basiliximab induction was not associated with lower rejection rates and did not allow delayed tacrolimus introduction.
Authors: M P Nair; M R Nampoory; K V Johny; J N Costandi; M Abdulhalim; W El-Reshaid; I Al-Muzairai; V T Ninan; M Samhan; M Al-Mousawi Journal: Transplant Proc Date: 2001-08 Impact factor: 1.066
Authors: Wai H Lim; Steve J Chadban; Scott Campbell; Hannah Dent; Graeme R Russ; Stephen P McDonald Journal: Nephrology (Carlton) Date: 2010-04 Impact factor: 2.506
Authors: Teun van Gelder; Helio Tedesco Silva; Johan W de Fijter; Klemens Budde; Dirk Kuypers; Gunnar Tyden; Aleksander Lohmus; Claudia Sommerer; Anders Hartmann; Yann Le Meur; Michael Oellerich; David W Holt; Burkhard Tönshoff; Paul Keown; Scott Campbell; Richard D Mamelok Journal: Transplantation Date: 2008-10-27 Impact factor: 4.939
Authors: Lisa M Willoughby; Mark A Schnitzler; Daniel C Brennan; Brett W Pinsky; Nino Dzebisashvili; Paula M Buchanan; Luca Neri; Lisa A Rocca-Rey; Kevin C Abbott; Krista L Lentine Journal: Transplantation Date: 2009-05-27 Impact factor: 4.939